Skip to content
DataLookout
Menu

PREDICT-HPNCT04844359

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words
    • Primary endpoints: details revised at 17 of 40 entries
    • Trial completed
  2. Notable Primary completion date: Jul 30, 2025 to Jul 30, 2026
    • Study completion date: Jul 31, 2025 to Jul 31, 2026
    v9
  3. Notable Primary completion date: Jan 2025 to Jul 30, 2025v8 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 135 to confirmed 137
    • Study completion date: Jan 2026 to Jul 31, 2025
    • Site details revised at 7 of 7 sites
  4. Minor Study sites: 6 to 7
    • Collaborators: 5 to 6
    v6
  5. Notable Eligibility criteria shortened, about 5 words
    • Study sites: 5 to 6
    • Collaborators: 4 to 5
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Primary completion date: Jan 2024 to Jan 2025
    • Eligibility criteria shortened, about 2 words
    • Study completion date: Jan 2025 to Jan 2026
    • Site details revised at 3 of 5 sites
    v4
  2. Notable Primary completion date: Jan 2023 to Jan 2024v3
  3. Notable Primary endpoints revised (40)v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to absolute FVC (percent predicted) decline ≥10 percent
Timeframe: Up to 24 months
Time to absolute DLCO (percent predicted) decline ≥10 percent
Timeframe: Up to 24 months
Time to relative FVC (percent predicted) decline ≥10 percent
Timeframe: Up to 24 months
Time to relative DLCO (percent predicted) decline ≥10 percent
Timeframe: Up to 24 months
Time to relative DLCO (percent predicted) decline ≥15 percent
Timeframe: Up to 24 months
Time to first adjudicated acute chronic hypersensitivity pneumonitis exacerbation
Timeframe: Up to 24 months
Need for a new course of oral or intravenous steroids
Timeframe: Up to 24 months
Time to death from any cause
Timeframe: Up to 24 months
Change from baseline in St. George's Respiratory Questionnaire total score at month 6
Timeframe: 6 months
Change from baseline in St. George's Respiratory Questionnaire total score at month 12
Timeframe: 12 months
Change from baseline in St. George's Respiratory Questionnaire total score at month 18
Timeframe: 18 months
Change from baseline in St. George's Respiratory Questionnaire total score at month 24
Timeframe: 24 months
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 6
Timeframe: 6 months
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 12
Timeframe: 12 months
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 18
Timeframe: 18 months
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 24
Timeframe: 24 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 6
Timeframe: 6 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 12
Timeframe: 12 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 18
Timeframe: 18 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 24
Timeframe: 24 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 6
Timeframe: 6 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 12
Timeframe: 12 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 18
Timeframe: 18 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 24
Timeframe: 24 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 6
Timeframe: 6 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 12
Timeframe: 12 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 18
Timeframe: 18 months
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 24
Timeframe: 24 months
Change from baseline in CT visual (≥10 percent) score at month 12
Timeframe: 12 months
Change from baseline in CT visual (≥10 percent) score at month 24
Timeframe: 24 months
Change from baseline in CT quantitative (≥3.4) score at month 12
Timeframe: 12 months
Change from baseline in CT quantitative (≥3.4) score at month 24
Timeframe: 24 months
Change from baseline in 6-min walk distance at month 6
Timeframe: 6 months
Change from baseline in 6-min walk distance at month 12
Timeframe: 12 months
Change from baseline in 6-min walk distance at month 18
Timeframe: 18 months
Change from baseline in 6-min walk distance at month 24
Timeframe: 24 months
Rate of decline in FVC (percent predicted) over 24 months
Timeframe: Up to 24 months
Rate of decline in FVC (ml) over 24 months
Timeframe: Up to 24 months
Rate of decline in DLCO (percent predicted) over 24 months
Timeframe: Up to 24 months
Rate of decline in DLCO (mmol/min/kpa) over 24 months
Timeframe: Up to 24 months

Sites

7 sites in 1 country